Skip to content

Insider · CIK 0001922605

Wendy Chung

director

Files at RLYB (Rallybio Corp), PRME (Prime Medicine, Inc.). First filing -, latest -.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Sep 16, 2026RLYB
Rallybio Corp
MOption exercise
Common Stock
+3,562$2.38$8,4783,56224 d ago
Sep 16, 2026RLYB
Rallybio Corp
MOption exercise
Option (Right to Buy)derivative
-3,562$0.00$0024 d ago
Aug 1, 2025PRME
Prime Medicine, Inc.
DDisposition to issuer
Stock Option (right to buy)derivative
-13,510--0Aug 5, 2025
Aug 1, 2025PRME
Prime Medicine, Inc.
AGrant or award
Stock Option (right to buy)derivative
+13,510--13,510Aug 5, 2025
Aug 1, 2025PRME
Prime Medicine, Inc.
DDisposition to issuer
Stock Option (right to buy)derivative
-9,006--0Aug 5, 2025
Aug 1, 2025PRME
Prime Medicine, Inc.
AGrant or award
Stock Option (right to buy)derivative
+9,006--9,006Aug 5, 2025
Aug 1, 2025PRME
Prime Medicine, Inc.
DDisposition to issuer
Stock Option (right to buy)derivative
-39,062--0Aug 5, 2025
Aug 1, 2025PRME
Prime Medicine, Inc.
AGrant or award
Stock Option (right to buy)derivative
+39,062--39,062Aug 5, 2025
Aug 1, 2025PRME
Prime Medicine, Inc.
DDisposition to issuer
Stock Option (right to buy)derivative
-45,000--0Aug 5, 2025
Aug 1, 2025PRME
Prime Medicine, Inc.
AGrant or award
Stock Option (right to buy)derivative
+45,000--45,000Aug 5, 2025
Jun 4, 2025PRME
Prime Medicine, Inc.
AGrant or award
Stock Option (right to buy)derivative
+55,000$0.00$055,000Jun 5, 2025
May 13, 2025RLYB
Rallybio Corp
AGrant or award
Option (Right to Buy)derivative
+28,500$0.00$028,500May 15, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Wendy Chung: insider trades and track record | InsiderTell